Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -66.37% | 7.81% | 8.69% | -45.40% | -64.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.37% | 7.81% | 8.69% | -45.40% | -64.91% |
| Cost of Revenue | -95.94% | -17.36% | 20.82% | -48.19% | -57.38% |
| Gross Profit | 12.68% | 49.11% | -13.36% | -41.29% | -76.17% |
| SG&A Expenses | 8.07% | 17.96% | 10.81% | -8.82% | -32.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.37% | 8.49% | 14.70% | -17.50% | -40.22% |
| Operating Income | -14.19% | -9.06% | -21.81% | -34.57% | 13.56% |
| Income Before Tax | -26.58% | -117.91% | -57.22% | -102.56% | 5.92% |
| Income Tax Expenses | -- | -197.22% | -38.51% | -255.29% | -371.43% |
| Earnings from Continuing Operations | -28.87% | -113.73% | -57.65% | -99.56% | 8.15% |
| Earnings from Discontinued Operations | -428.96% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 28.00% | 317.52% | -29.91% | -5.62% | -36.87% |
| Net Income | -81.43% | -89.25% | -62.41% | -104.07% | 17.03% |
| EBIT | -14.19% | -9.06% | -21.81% | -34.57% | 13.56% |
| EBITDA | -15.41% | -23.08% | -39.28% | -62.79% | 7.96% |
| EPS Basic | -33.33% | -79.17% | -60.00% | -110.00% | 21.74% |
| Normalized Basic EPS | 7.69% | 100.00% | -33.33% | -66.67% | 13.33% |
| EPS Diluted | -33.33% | -79.17% | -60.00% | -110.00% | 21.74% |
| Normalized Diluted EPS | 7.69% | 100.00% | -33.33% | -66.67% | 13.33% |
| Average Basic Shares Outstanding | 33.89% | 4.64% | 4.15% | 3.12% | 3.51% |
| Average Diluted Shares Outstanding | 33.89% | 4.64% | 4.15% | 3.12% | 3.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |